Vidofludimus Calcium Safely Reduced RRMS Brain Lesions

Vidofludimus Calcium Safely Reduced RRMS Brain Lesions

328083

Vidofludimus Calcium Safely Reduced RRMS Brain Lesions

Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosis (RRMS), data from the Phase 2 EMPhASIS clinical trial shows. Top-line results from EMPhASIS were reported by the therapy’s developer Immunic Therapeutics in 2020. Researchers at Immunic and other institutions now have published full trial results in the Annals of Clinical and Translational Neurology. The study, “A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective…

You must be logged in to read/download the full post.